Ochsner Participating in Largest Heart Failure Clinical Trial in US

SAP Partners | <b>Ochsner</b>

Enrollment for GUIDE-HF Clinical Trial Now Open

The John Ochsner Heart and Vascular Institute (JOHVI) is currently enrolling heart failure patients in the GUIDE-HF clinical trial—the largest heart failure (HF) medical device trial in the United States. Heart failure is the leading cause of hospitalization in America for adults over the age of 65 and Louisiana has the 5th highest death rate from cardiovascular disease in the country.

The GUIDE-HF clinical trial is an investigational device exemption (IDE) study aimed at evaluating improved survival and quality of life with Abbott’s CardioMEMS™ HF System, which supports heart failure management by measuring pulmonary artery pressure (PAP) from within the body. Building on previous clinical trials, the GUIDE-HF trial will study whether the implanted device can reduce heart failure hospitalization and improve survival and quality of life for people living with Class II, Class III or Class IV heart failure.

Once implanted via a minimally invasive procedure, the CardioMEMS™ HF System’s sensor transmits critical information about a patient’s pressure readings and heart failure status to a clinician, without the need for additional clinic or hospital visits. This data provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.

To read the full press release click here.